TME Pharma N.V. (ALTME.PA)

EUR 0.06

(1.1%)

Revenue Summary of TME Pharma N.V.

  • TME Pharma N.V.'s latest annual revenue in 2023 was 17 Thousand EUR , down 0.0% from previous year.
  • TME Pharma N.V.'s latest quarterly revenue in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • TME Pharma N.V. reported a annual revenue of - EUR in annual revenue 2022, down -100.0% from previous year.
  • TME Pharma N.V. reported a annual revenue of 33.00 EUR in annual revenue 2021, down -5.71% from previous year.
  • TME Pharma N.V. reported a quarterly revenue of 8500.00 EUR for 2023 Q4, down 0.0% from previous quarter.
  • TME Pharma N.V. reported a quarterly revenue of 17 Thousand EUR for 2023 FY, down 0.0% from previous quarter.

Annual Revenue Chart of TME Pharma N.V. (2023 - 2014)

Historical Annual Revenue of TME Pharma N.V. (2023 - 2014)

Year Revenue Revenue Growth
2023 17 Thousand EUR 0.0%
2022 - EUR -100.0%
2021 33.00 EUR -5.71%
2020 35.00 EUR -77.27%
2019 154.00 EUR 0.0%
2018 - EUR -100.0%
2017 234 Thousand EUR 181.93%
2016 83 Thousand EUR 93.02%
2015 43 Thousand EUR 72.0%
2014 25 Thousand EUR 0.0%

Peer Revenue Comparison of TME Pharma N.V.

Name Revenue Revenue Difference
ABIONYX Pharma SA 4.64 Million EUR 99.634%
ABIVAX Société Anonyme 4.62 Million EUR 99.632%
Adocia SA 2.15 Million EUR 99.209%
Aelis Farma SA 9.05 Million EUR 99.812%
Biophytis S.A. - EUR -Infinity%
Advicenne S.A. 3.15 Million EUR 99.46%
genOway Société anonyme 20.04 Million EUR 99.915%
IntegraGen SA 12.53 Million EUR 99.864%
Medesis Pharma S.A. 300.03 Thousand EUR 94.334%
Neovacs S.A. 533.41 Thousand EUR 96.813%
NFL Biosciences SA - EUR -Infinity%
Plant Advanced Technologies SA 1.68 Million EUR 98.989%
Quantum Genomics Société Anonyme 19.79 Thousand EUR 14.124%
Sensorion SA 4.74 Million EUR 99.642%
Theranexus Société Anonyme 296.33 Thousand EUR 94.263%
Valbiotis SA 4.73 Million EUR 99.641%
TheraVet SA 1.07 Million EUR 98.423%
Valerio Therapeutics Société anonyme 1.8 Million EUR 99.056%
argenx SE 1.13 Billion EUR 99.999%
BioSenic S.A. 543 Thousand EUR 96.869%
Celyad Oncology SA 102 Thousand EUR 83.333%
DBV Technologies S.A. - EUR -Infinity%
Galapagos NV 239.72 Million EUR 99.993%
Genfit S.A. 28.56 Million EUR 99.94%
GeNeuro SA - EUR -Infinity%
Hyloris Pharmaceuticals SA 2.08 Million EUR 99.185%
Innate Pharma S.A. 51.9 Million EUR 99.967%
Inventiva S.A. 17.47 Million EUR 99.903%
MaaT Pharma SA 2.22 Million EUR 99.237%
MedinCell S.A. 9.16 Million EUR 99.814%
Nanobiotix S.A. 30.05 Million EUR 99.943%
Onward Medical N.V. 532 Thousand EUR 96.805%
Oryzon Genomics S.A. 14.19 Million EUR 99.88%
OSE Immunotherapeutics SA 2.22 Million EUR 99.237%
Oxurion NV 263 Thousand EUR 93.536%
Pharming Group N.V. 245.31 Million EUR 99.993%
Poxel S.A. 1.98 Million EUR 99.142%
GenSight Biologics S.A. 1.26 Million EUR 98.658%
Transgene SA 1.18 Million EUR 98.564%
Financière de Tubize SA - EUR -Infinity%
UCB SA 5.25 Billion EUR 100.0%
Valneva SE 153.71 Million EUR 99.989%
Vivoryon Therapeutics N.V. -3.62 Million EUR 100.47%